Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 486757 vs codeine vs placebo in persistent postviral cough
2004-004113-42Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SCH-486757 in Postviral cough (3 arms), sponsored by Merck & Co. Primary endpoint: Primary: change in cough severity score over 5 days. Started Mar 2005; status: terminated.
02
Drugs
SCH-486757
03
Conditions
Postviral cough
Beyond the preview
Go deeper on 2004-004113-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004113-42.